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ABSTRACT 
Since the first association between HLA and diseases of native kidneys was described almost 50 
years ago, technological and conceptual advances in HLA biology and typing, together with better 
case ascertainment, have led to an improved understanding of HLA associations with a variety of 
renal diseases. A substantial body of evidence now supports the existence of HLA genetic 
associations in the field of renal disease beyond the role of HLA in allogeneic responses in transplant 
recipients. Allomorphs of HLA have emerged as important risk factors in most immune-mediated 
renal diseases, which, together with other genetic and environmental factors, lead to loss of tolerance 
and autoimmune-mediated renal inflammation. HLA associations have also been described for renal 
diseases that are less traditionally seen as autoimmune or immune-mediated. Here, we review 
essential concepts in HLA biology and the association of HLA with diseases of the native kidneys, 
and describe the current understanding of the epistatic and mechanistic bases of HLA-associated 
kidney disease. Greater understanding of the relationship between HLA and kidney function has the 
potential not only to further the understanding of immune renal disease at  a fundamental level but 
also to lead to the development and application of more effective, specific and less toxic therapies for 
kidney diseases. 
 
INTRODUCTION 
The adaptive immune system has evolved to meet and manage infectious threats. A central 
component of this system is the contextual recognition of peptide antigens and differentiation of T 
cells, with the subsequent development of protective immunity. These key features occur through the 
recognition of peptides bound to major histocompatibility complex (MHC) — or in humans, human 
leukocyte antigen (HLA) — by T cells that bear unique, highly diverse T cell receptors (TCRs). The 
evolution of the adaptive immune system not only required the development of mechanisms to delete 
T cells that have a strong affinity for self-peptides and proteins but also favoured the development of 
a polygenic and highly polymorphic HLA system to enable the specific recognition of a diverse set 
of peptides for presentation to T cells. 
A major cost of this powerful and specific system is the aberrant recognition of self -peptides by 
TCRs, leading to the development of autoimmune disease. The risk associated with such 
misidentification is highlighted by the fact that autoimmune diseases affect 7.6–9.4% of the world’s 
population1. With some exceptions, autoimmune diseases are typically thought to evolve via a 
multistep process2, involving loss of tolerance to one or more self-antigens owing to interactions 
between genetic susceptibility factors and environmental risk factors, followed by amplification of 
disease manifestations via the activation of positive feedback loops resulting from disordered 
immune responses. Tolerance is a state that in health is established and maintained by both central 
and peripheral mechanisms. Central tolerance involves the selection of T and B lymphocytes in the 
thymus and bone marrow, respectively. The selection of T cells, as well as their ability to recognize 
pathogenic peptides, requires interactions between antigenic peptides bound to MHC (or HLA) 
molecules. Two classes of MHC molecules exist: MHC class I molecules are found on the surface of 
all nucleated cells in the body and present peptides to CD8+ T cells. MHC class II molecules are 
normally expressed only by antigen-presenting cells, such as dendritic cells, mononuclear phagocytes 
and B cells, and present peptides to CD4+ T cells. MHC class I and class II molecules therefore 
define the repertoire of CD8+ and CD4+ T cells, respectively. Interestingly, almost all autoimmune 
diseases tend to be more common in people with certain HLA types, highlighting the key role of  
HLA alleles in maintaining tolerance and, conversely, in the development of autoimmunity. HLA is 
therefore a key genetic risk factor in autoimmune disease, and understanding the functions of HLA is 
fundamental to unravelling the pathogenesis of autoimmune diseases. 
Since the initial studies of HLA and disease that essentially founded the field of immunogenetics, 
key advances have been made in our understanding of the immune system, including mechanisms 
involved in providing protection from infectious diseases, immunological memory, loss of tolerance 
and allorecognition3. In the past 10 years, technical advances have led to the associations between 
HLA in disease being better defined and provided new insights into the underlying mechanisms 3. 
This new understanding has the potential to identify better, more specific therapies for diseases 
involving HLA. This Review summarizes basic concepts pertaining to HLA and disease and assesses 
the growing literature in the field of HLA in diseases of native kidneys. We review the mechanistic 
links underlying the associations between HLA and kidney diseases and discuss how these links 
might provide insights into disease pathogenesis as well as the clinical implications of these insights. 
Although HLA is a critical element of renal transplantation, the involvement of HLA and its role in 
allorecognition is mechanistically distinct from the mechanisms described in this Review4,5,6 and is 
not discussed here. 
FUNDAMENTAL APSECTS OF HLA BIOLOGY 
The HLA is a fundamental component of adaptive immunity. Following their intracellular 
processing, self-peptides and non-self-peptides are loaded into grooves within HLA complexes for 
presentation to TCRs. The combination of the peptide and the MHC complex is recognized by the 
TCR. This specific recognition is a central tenet of antigen specificity, which itself is the critical 
feature that defines the adaptive immune system. 
HLA types and the HLA locus 
The genes that encode the proteins of the MHC (or HLA in humans) are located on chromosome 6. 
The MHC region is the largest and most polymorphic area of the genome, containing several classes 
of genes that are important in immune function, including the antigen-presenting MHC class I alleles 
(in humans, the HLA-A, HLA-B and HLA-C alleles) and the MHC class II genes (in humans, the 
HLA-DR, HLA-DP and HLA-DQ genes) (Figure 1a). HLA class I molecules are composed of a 
single α-chain that is non-covalently bound to β2-microglobulin, with the α1 and α2 segments of the 
α-chain forming the peptide-binding cleft. By contrast, MHC class II molecules consist of both an α-
chain and a β-chain, with the α1 and β1 segments forming the peptide-binding cleft (Figure 1b). The 
α-chain of HLA-DR is essentially invariant, but functionally relevant polymorphisms exist in both 
the α-chains and β-chains for HLA-DQ and HLA-DP (Table 1). Other genes within the HLA class II 
region encode HLA-DO and HLA-DM, proteins that do not present peptides but are important to the 
process of loading peptides into HLA-DR, HLA-DP and HLA-DQ. HLA-DM is important in the 
loading of peptides into MHC class II whereas HLA-DO is a negative regulator of HLA-DM. Other 
MHC class I genes include the largely monomorphic HLA-E, HLA-F and HLA-G genes, which 
interact with natural killer (NK) cells and, in the case of HLA-G, help maintain immune tolerance to 
the fetus during pregnancy. 
The MHC class I and class II genes are separated by the so-called MHC class III region, which 
includes genes that encode complement components, heat shock protein 70 (HSP70), tumour necrosis 
factor (TNF) and receptor for advanced glycosylation end products (RAGE; also known as AGER). 
These and other non-MHC class I and MHC class II genes within the MHC region have important 
biological functions in immune and non-immune kidney diseases, and their presence within the 
broader MHC locus can complicate studies of the association between HLA and disease7. This 
Review focuses on the roles of the MHC class I and class II molecules that present antigen to T cells 
(that is, HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ and HLA-DP) in kidney disease. 
Humans inherit multiple MHC class I and class II alleles from each parent as a haplotype on 
chromosome 6. As of July 2018, 9,341 different HLA-A, HLA-B and HLA-C proteins and 5,355 
different HLA-DR, HLA-DQ and HLA-DP proteins were known to exist, derived from 
polymorphisms in the HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB, HLA-DQA, HLA-DQB, 
HLA-DPA and HLA-DPB genes. Any individual can express up to six HLA class I alleles and eight 
class II alleles, highlighting the complexity of this system. With the exception of HLA-DP alleles, 
HLA alleles are often in strong linkage disequilibrium, tending to segregate together in specific 
haplotypes, such as the ‘8.1 ancestral haplotype’8. The most relevant HLA polymorphisms result in 
amino acid substitutions that predominantly involve peptide-binding sites and/or potential TCR 
contact areas. Therefore, it is likely that this highly polymorphic and polygenic system evolved to 
favour the effective display of a broad array of infection-related and self-peptides to CD4+ and 
CD8+ T cells. 
HLA and peptide presentation 
Unlike antibodies, T cells do not recognize intact proteins. Rather, via their  clonotypic αβ T cell 
antigen receptor, T cells bind to peptides presented by molecules encoded by the MHC (in humans, 
HLA). As mentioned above, self and foreign proteins are processed intracellularly. Classically, 
proteins that exist outside the cell and are degraded in endocytic vesicles via protease-mediated 
degradation bind to MHC class II molecules, whereas peptides that bind to MHC class I are derived 
from the processing of cytosolic proteins in the proteasome. In addition, exogenous proteins are 
presented by MHC class I molecules on some antigen-presenting cells (for example, some dendritic 
cells) in a process known as cross presentation9. Peptides are loaded onto MHC class I or MHC class 
II molecules within a series of pockets located within the antigen-binding cleft. One or two pockets 
typically define the peptide-binding preferences of a given MHC molecule. Although the two classes 
of MHC molecules have a similar overall 3D architecture, differences exist within their peptide 
antigen-binding clefts. Namely, the amino termini and carboxyl termini of MHC class I molecules 
are ‘pinched off’, favouring the binding of shorter-length peptides (fewer than ten amino acids), 
whereas the peptide-binding grooves of MHC class II molecules are open-ended, thereby permitting 
peptides of much longer length to bind10. The polymorphic composition of the HLA locus enables 
each HLA allomorph to have a distinct peptide-binding preference through which it shapes the T cell 
repertoire. For example, the HLA-DR allomorphs HLA-DR1 and HLA-DR15 exhibit different 
peptide-binding characteristics, accounting for their ability to provide protection from, and increase 
the risk of, Goodpasture disease (also known as anti-glomerular basement membrane (GBM) 
disease), respectively11. 
To cope with the myriad of peptide–MHC complexes that are presented on the surface of cells, the 
TCR itself is highly variable. The αβ-TCR is composed of two chains, each of which is composed of 
multiple gene segments encoded within the variable domain. Moreover, the existence of non-
nucleotide-encoded additions and/or deletions at gene junctional boundaries increases the sequence 
diversity of TCRs. Current estimates suggest that up to 1 × 1015 different TCRs exist in the human 
body, which, after thymic selection, is reduced to 1 × 108 TCRs12. 
Interaction between the TCR and the peptide–MHC complex involves the specific and simultaneous 
co-recognition of the peptide and the MHC molecule in a phenomenon known as MHC restriction 
(Figure 1c) and is the critical event that determines effective T cell immunity. Structural studies over 
the past 20 years have provided fundamental insights into the molecular determinants of this key 
recognition event and illuminated key facets of immunology (for example, by providing insights into 
how MHC polymorphisms shape TCR recognition, T cell cross reactivity, alloreactivity and 
autoreactivity) as well as mechanisms of biased TCR usage and viral immunity10. Although much 
remains to be learned in the field of antigen recognition, our ability to harness these mechanisms 
holds promise for the future, including the development of diagnostics centred on TCR repertoire 
usage and precision medicine approaches. 
HLA typing and nomenclature 
Changes to HLA nomenclature and methods for HLA typing have implications for studies of HLA 
associations with disease (Box 1). The origins of HLA typing date back to the 1960s, with the 
generation of antibodies that recognized HLA complexes on the cell surface, such as HLA-A2, in 
which the ‘2’ describes a distinct variant or allomorph in HLA-A13. The advent of molecular typing 
enabled the identification of genes expressing HLA class I α-chains, HLA class II α-chains and HLA 
class II β-chains and provided insights into the complexity of HLA class II. Use of this technology 
enabled the nomenclature of HLA to become both more complex and more accurate by including a 
four-digit descriptor for each chain. This nomenclature was later expanded to accommodate the 
discovery of synonymous coding and non-coding HLA polymorphisms14 (Figure 1d). In a research 
setting, single-nucleotide polymorphism (SNP)-based typing of HLA encoding genes with allelic 
imputation is common. Most genotyping methods result in some genotyping and allelic ambiguity in 
that results might be consistent with several alleles at a particular locus. Fortunately, however, this 
ambiguity often does not have major implications for association studies of immune-mediated kidney 
diseases as it often pertains to polymorphisms outside of peptide binding and TCR contact regions or 
to very rare alleles. The characteristics of the antigen-presenting HLA class I proteins (HLA-A, 
HLA-B and HLA-C) and HLA class II proteins (HLA-DR, HLA-DQ and HLA-DP) are summarized 
in Table 1. 
HLA AND KIDNEY DISEASE 
HLA types give rise to risk alleles, protective alleles and dominantly protective alleles, which are 
important in several aspects of disease. Different autoimmune kidney diseases arise from the 
interactions of self-peptides with specific HLA molecules, as evidenced by the association of HLA 
types with specific diseases. The first association of HLA with renal disease was reported in 196913. 
Early studies of the association between HLA and kidney disease often involved small numbers of 
patients; in the past decade, larger studies have been better able to dissect the contributions of 
individual HLA types in linkage disequilibrium within a haplotype to disease. HLA associations with 
disease have most commonly been studied by comparing HLA types among patients with a disease 
with those of individuals within a control cohort. However, simply comparing HLA types in patients 
with disease to those without, particularly without detailed clinical phenotyping, might miss some of 
the important but subtle potential effects of HLA types, including the influence of HLA on the age of 
disease onset, disease severity, disease phenotype and rates of disease-triggering events. Some 
kidney diseases (for example, membranous nephropathy mediated by autoimmunity to the secretory 
phospholipase A2 receptor (PLA2R) and anti-neutrophil cytoplasmic antibody (ANCA)-associated 
glomerulonephritis) have a clear immunological basis15 and fairly logical potential mechanisms by 
which different HLA types might modify disease risk. In other kidney conditions, including end-
stage renal disease (ESRD) in general, linkage disequilibrium with other inflammation-related genes 
in the MHC class III region might confound the HLA data. Although the association of HLA types to 
disease can be similar across ethnic groups (as in the increased risk of Goodpasture disease conferred 
by the expression of HLA-DR15)16,17,18, they can also differ (as reported for HLA risk alleles in the 
context of membranous nephropathy)19,20,21,22. Of note, in addition to changes in HLA nomenclature 
and HLA typing methods (Box 1), changes in diagnostic criteria and classification of kidney diseases 
have further complicated studies of the association of HLA alleles with kidney diseases. 
Sites of HLA expression 
HLA is clearly critical within lymphoid organs, where HLA–peptide complexes participate in the 
selection of T and B lymphocytes to establish central tolerance and to activate naive T cells or 
maintain them in a quiescent state (Figure 2). Kidney disease can arise from the effects of HLA in 
the lymphoid organs or in the kidney. Naive CD4+ and CD8+ T cells are activated in secondary 
lymphoid organs including lymph nodes and spleen, where antigen-specific CD4+ T cells also have 
an essential role in antibody production by interacting with peptides presented by HLA class II 
molecules on B cells. Effector CD8+ T cells, as well as both T helper 1 (TH1) and T helper 17 (TH17) 
CD4+ T cells, can injure the kidney, both by recognizing intrarenal antigens, including, at least for 
CD4+ T cells, antigens presented within the glomerular microvasculature23,24,25 (Figure 3). The 
expression of HLA class I molecules on nucleated cells within the kidney enables effector CD8+ T 
cells to recognize cells that have been infected with virus and cells displaying peptides derived from 
intracellular autoantigens. The role of HLA class II molecules in antigen recognition by effector or 
regulatory CD4+ cells within the kidney is more complex. Resident and infiltrating antigen-
presenting cells within the kidney — also known as renal mononuclear phagocytes — constitutively 
express MHC class II and are prominent in the tubulointerstitium26,27. MHC class II is also present on 
B cells and tubular epithelial cells in the tubulointerstitium. In glomeruli, MHC class II is expressed 
by luminal monocytes24 and on infiltrating macrophages and dendritic cells under inflammatory 
conditions28. Non-phagocytic intrinsic glomerular cells, including endothelial cells and podocytes, 
can also be induced to express MHC class II in response to a variety of inflammatory stimuli, 
potentially allowing them to present antigen to effector CD4+ T cells29,30. Moreover, tubulointerstitial 
B cell aggregates are present in at least some types of glomerulonephritis, and activated antigen-
specific B cells are highly effective antigen-presenting cells that express MHC class II31,32. 
Under physiological conditions, MHC class II expression by tubular cells and perhaps intrinsic 
glomerular cells might help to maintain peripheral tolerance but might exert pro-inflammatory effects 
under certain conditions33,34,35. Thus, in addition to the effects of HLA in lymphoid organs, it is 
plausible that different HLA allomorphs expressed by renal cells or renal mononuclear phagocytes 
might contribute mechanistically to renal disease. 
FROM ASSOCIATION TO MECHANISTIC INSIGHTS 
Improved understanding of the molecular sequence and structure of most HLA molecules has 
enabled comparison of the commonalities and differences between risk, neutral and protective 
alleles36. This comparative approach has been frequently applied to the study of risk alleles in 
autoimmune disease, including Goodpasture disease and membranous nephropathy16,19. Individual 
amino acid differences in HLA alleles can dictate structural determinants that define peptide binding 
and therefore antigen presentation — features that can be interrogated in functional and structural 
studies11,37. However, intermolecular and intramolecular epitope spreading complicates assessment of 
HLA–peptide interactions in autoimmune disease, as the multiplicity of epitopes in more than one 
autoantigen makes definitive identification of the critical autoantigenic peptides difficult. Some 
systemic autoimmune diseases, such as systemic lupus erythematosus (SLE), feature loss of tolerance 
to multiple autoantigens. Even organ-specific autoimmune diseases in which one might expect only 
one autoantigen can often involve loss of tolerance to multiple autoantigens; for example, type 1 
diabetes mellitus (T1DM) features loss of tolerance to multiple pancreatic β-cell antigens38. 
However, several autoimmune renal diseases, including Goodpasture disease, proteinase 3 ANCA-
associated vasculitis (PR3-AAV), myeloperoxidase (MPO)-AAV and PLA2R-induced membranous 
nephropathy seem to involve a single or at least a dominant autoantigenic target, at least according to 
our current knowledge of disease pathogenesis. 
HLA types may predispose to or protect against the development of autoimmune disease through 
multiple mechanisms such as through changes in the expression or stability of HLA, antigenic 
peptide modifications, shifts in the peptide-binding register between different HLA molecules or the 
development of a pathogenic or protective antigen-specific T cell repertoire3,11,37,39,40,41. Thus, the 
relationship between HLA–peptide complexes, autoreactive TCRs and cellular phenotype is of 
utmost importance in determining whether an interaction will induce tolerance or autoimmunity and 
whether it could potentially be harnessed for therapeutic purposes. However, in general, little is 
known about how HLA allomorphs, and the differences in peptide binding to different HLA 
allomorphs, affect the deletion, selection and subsequent activation of T cells bearing autoreactive 
TCRs. In autoimmune diseases, knowledge of immunodominant peptide epitopes and their binding to 
different HLA molecules is critical to understanding the mechanisms by which different HLA 
allomorphs influence the risk of disease. Various techniques have therefore been developed to define 
the mechanisms of HLA associations (Box 2). Although human studies are critical in any 
mechanistic study of HLA associations, HLA transgenic mice have emerged as important tools in in 
vivo studies. 
Goodpasture disease is a useful prototypic model for mechanistic studies of renal autoimmune 
disease owing to the presence of a dominant autoantigen (non-collagenous domain of the α3 chain of 
type IV collagen (α3(IV)NC1)) with defined T cell and B cell epitopes, high sequence homology 
between human and mouse α3(IV)NC1, strong positive (HLA-DR15) and dominant-negative HLA 
associations (HLA-DR1 and HLA-DR7) and clear diagnostic criteria16,42. Loss of tolerance to 
α3(IV)NC1 and the development of Goodpasture disease has been studied in HLA-DR transgenic 
mice lacking murine MHC class II, wherein the CD4+ T cell repertoire is based on the interactions of 
mouse proteins with human HLA-DR11,43,44. These transgenic mice have been engineered to express 
the invariant HLA-DRA1*01:01 allele, with either HLA-DRB1*15:01 (HLA-DR15+) or HLA-
DRB1*01:01(HLA-DR1+) or both HLA-DRB1 alleles (HLA-DR15+DR1+). Consistent with sentinel 
studies in humans45, an epitope derived from α3(IV)NC1, α3135–145(mouse α3136–146), was established 
as the critical and disease-inducing epitope in disease-sensitive HLA-DR15+ mice. However, in the 
presence of the dominantly protective HLA-DR1 allele, the α3135–145 epitope does not induce pro-
inflammatory responses in mice or in humans, explaining the dominantly protective effect of HLA-
DR1 on the risk conferred by HLA-DR1511,44 (Figure 4a). 
This phenomenon of dominant HLA-mediated protection against autoimmunity could conceivably 
involve several mechanisms, including the deletion or activation-induced cell death of autoreactive T 
cells, epitope capture by the protective HLA allomorph or induction of epitope-specific regulatory T 
(Treg) cells. In HLA transgenic mice and in humans, dominant protection against autoreactivity to 
α3(IV)NC1 is dependent on polymorphisms that distinguish HLA-DR15 and HLA-DR1 and affect 
the presentation of the α3135–145 epitope, causing a shift in the binding register11. The structure of the 
HLA-DR15 and HLA-DR1 peptide-binding pockets changes the presentation of α3135–145 to CD4+ T 
cells, leading to fundamental differences in their associated TCR repertoires and phenotype. Indeed, 
α3135–145-specific CD4+ cells in naive mice and in healthy humans show pro-inflammatory capacities 
in the context of HLA-DR15 but generate predominantly Treg cells in the context of HLA-DR1 
(Figure 4a). The power of antigen-specific Treg cells in inducing tolerance was demonstrated by in 
vitro findings in humans and mice and by in vivo findings in mice, showing that T reg cells generated 
in response to HLA-DR1 presentation of α3135–145 suppressed the effects of autoreactive conventional 
T cells generated in response to HLA-DR1511. Similar processes might operate in other diseases. In 
particular, HLA-DQ6 exhibits a similar dominantly protective effect on the risk conferred by HLA-
DQ8 in T1DM, with studies in diabetes-prone non-obese diabetic mice implicating Treg cells in HLA-
DQ6-mediated protection46. 
The opportunity exists to apply these types of mechanistic approaches to the study of other forms of 
renal disease, including membranous nephropathy, in which polymorphisms in the autoantigen 
PLA2R are epistatically linked to HLA. In addition, applying concepts explored in non-renal 
autoimmune diseases to renal disease might provide insights into how HLA contributes to renal 
disease. In rheumatoid arthritis, for example, the amino acid composition at position 13 in the base of 
the peptide-binding groove of HLA class II molecules, as well as the shared epitope defined by 
amino acids 70–74 of the HLA-DR β-chain, defines the risk alleles HLA-DRB1*04:01, HLA-
DRB1*04:04 and HLA-DRB1*01:0147.  Citrullination of endogenous peptides promoted by cigarette 
smoking modifies the binding of peptides to HLA-DRB1*04:01 and HLA-DRB1*04:04 (but not the 
protective HLA-DRB1*04:02 allele) and stimulates autoreactive T cells37. In multiple sclerosis, 
studies have defined functional epistasis between HLA-DR15 and HLA-DR51. The HLA-
DRB1*15:01 and HLA-DRB5*01:01 alleles are in almost complete linkage disequilibrium: HLA-
DR51 modifies the strong pro-inflammatory effects of HLA-DR15 in experimental multiple sclerosis 
and might also modulate the pro-inflammatory effects of one or more microbial peptides. For 
instance, co-inheritance of HLA-DR15 and HLA-DR51 might in the past have increased survival 
following infection with particular life-threatening pathogens, through effective control of the 
infection (via HLA-DR15-mediated immunity) together with HLA-DR51–peptide interactions 
regulating the response to prevent lethal pro-inflammatory responses. These interactions might 
explain the strong linkage disequilibrium between HLA-DR15 and HLA-DR5148.  Studies in multiple 
sclerosis have also structurally and mechanistically demonstrated the subtleties that 
underpin molecular mimicry in this disease, with TCR engagement and T cell activation via HLA–
peptide complexes featuring a molecular hot spot common to different peptides that have only 
limited sequence homology to the autoreactive self-peptide41. 
Of note, the role of HLA in pathological inflammation is by no means confined to traditional 
autoimmune diseases. Alterations in HLA–peptide binding might also explain many type B adverse 
drug reactions(ADRs), as exemplified by the interactions of abacavir with HLA-B*57:0149, which 
are discussed below (Figure 4b). 
A plethora of studies have demonstrated pathogenic and protective HLA associations in autoimmune 
kidney diseases, including AAV, membranous nephropathy and lupus nephritis . Furthermore, HLA 
associations may also help define pathogenic mechanisms in other, non-autoimmune renal diseases 
(Table 2). These insights, together with advances in our understanding of disease pathogenesis and 
stratification, provide an opportunity to develop more specific treatments for kidney diseases.  
HLA ASSOCIATIONS IN RENAL DISEASES 
Autoimmune glomerulonephritis 
Goodpasture disease 
Type IV collagen (collagen IV) is an important component of the basement membrane in the kidney 
and other organs and is composed of six isomeric chains (α1–6)42. The presence of autoantibodies to 
the α3 chain of collagen IV results in Goodpasture disease, which is characterized by rapidly 
progressive glomerulonephritis and pulmonary haemorrhage. Both antibody production and cellular 
immunity are important in the pathogenesis of Goodpasture disease,  and specific epitopes of the 
autoantigen that elicit B cell and T cell responses have been defined44,45,50. The positive association 
of HLA-DR15 with Goodpasture disease is among the strongest reported for an autoimmune 
disease16. 
The first association of Goodpasture disease with an HLA allele was made in 1978 following the 
identification of HLA-DR2 using serotyping51. The advent of molecular techniques enabled the 
subdivision of HLA-DR2 into more specific allele groups, including HLA-DRB1*15 and HLA-
DRB1*16. A strong association between HLA-DRB1*15:01 and Goodpasture disease has since been 
demonstrated in several studies of European populations. The reported association between HLA-
DQB1*06:02 and Goodpasture disease is due to linkage disequilibrium between HLA-DQB1*06:02 
and HLA-DR1552,53,54,55. A meta-analysis in 1999 confirmed a strong association between HLA-
DRB1*15:01 and Goodpasture disease (OR 8.5) and identified a weaker positive association with 
HLA-DRB1*0416.  Conversely, HLA-DR1, HLA-DR716 and possibly HLA-DPB1*04:0156 confer a 
dominantly protective effect. More recently, studies of Japanese and Chinese populations have 
replicated the HLA-DR15 association17,18,57. The most recent of these also described a protective 
effect of HLA-DRB1*09:01 in a Han Chinese population57. HLA associations reported in 
Goodpasture disease are described in Supplementary Table 1. The coexistence of anti-GBM 
antibodies and MPO-ANCA in some individuals with Goodpasture disease is a well-recognized 
phenomenon58,59; it is feasible that HLA allomorphs contribute to the risk of ‘dual-positive’ disease. 
The mechanisms by which HLA-DR15 and HLA-DR1 confer susceptibility to and protection against 
Goodpasture disease have been defined (discussed above). The hypothesis that key structural 
differences between the binding pockets within the peptide-binding grooves of HLA-DR15 and 
HLA-DR1 (especially pocket 1 and pocket 4) might influence the presentation of α3(IV)NC116 is 
supported by structural and functional data using the immunodominant T cell epitope α3 135–145 44,45, 
which showed that polymorphic differences in HLA-DR15 and HLA-DR1 result in distinct peptide-
binding patterns, leading to the activation of distinct T cell repertoires. The phenotype of these T cell 
repertoires determines susceptibility to disease11. 
Membranous nephropathy 
Membranous nephropathy is one of the most common causes of nephrotic syndrome in adults. 
Histologically, this disease is characterized by the presence of subepithelial glomerular immune 
complex deposits and thickening of the basement membrane — a pattern of injury that is also 
associated with other diseases, including viral hepatitis and SLE, and with exposure to drugs and 
toxins such as penicillamine and gold (discussed below). In so-called primary membranous 
nephropathy, target autoantigens were unknown in most adults until the recognition of PLA2R, 
which is constitutively expressed at low levels on normal podocytes60. Circulating anti-PLA2R 
autoantibodies and PLA2R antigen expression in glomerular deposits are present in more than 70% 
of cases of idiopathic membranous nephropathy60,61. A different autoantigen, thrombospondin type-1 
domain-containing protein 7A, was subsequently identified in a proportion of patients with idiopathic 
membranous nephropathy who are anti-PLA2R-negative62. 
A summary of all HLA associations described in membranous nephropathy is provided in 
Supplementary Table 2. The first association was reported in 1979, with the finding of a 12-fold 
increased risk of membranous nephropathy associated with HLA-DR3 in an English cohort63; this 
association was subsequently corroborated in small French and German serological studies 64,65. A 
study that used an early technique for DNA analysis confirmed the HLA-DR3 association and 
identified HLA-DQA1 as a susceptibility factor66. The first genome-wide association study (GWAS) 
of membranous nephropathy and subsequent molecular typing studies identified HLA-DQA1 as the 
dominant risk locus22,67,68,69,70, with the rs2187668 risk allele conferring an increased risk of 
membranous nephropathy across multiple ethnic groups. It is possible that the HLA-DRB1*03:01 
(HLA-DR3) and HLA-DQA1*05:01–HLA-DQB1*02:01 (HLA-DQ2) associations represent a risk 
haplotype for membranous nephropathy21. Studies in Asian populations have consistently 
demonstrated an additional association of membranous nephropathy with HLA-DR15 — an 
allomorph that has been linked to several other autoimmune diseases including Goodpasture 
disease16. Two studies of Chinese individuals published in 2017 identified a strong link between 
membranous nephropathy and HLA-DRB1*15:0119,20, supporting earlier reports of a strong 
association between this disease and HLA-DR15 in Japanese populations (as HLA-DR2, the original 
serotype that included HLA-DR15)71,72,73. Ethnic differences in HLA associations in membranous 
nephropathy might reflect different background allele frequencies and/or indicate varying underlying 
disease mechanisms. 
SNPs in the PLA2R locus on chromosome 2q24 have also been associated with an increased risk of 
developing membranous nephropathy. Interestingly, inheritance of both the HLA-DQA1 and PLA2R 
risk alleles synergistically increases the risk of membranous nephropathy (OR 7.3–79.4), suggesting 
functional epistasis between HLA class II molecules and PLA2R21,22,67,68,69,70. Although the 
mechanisms that underpin the HLA associations with membranous nephropathy remain unclear, the 
combination of risk variants in HLA and PLA2R might alter the interaction between HLA class II 
molecules and autoantigen, enhancing antigen presentation, T cell activation and thus the production 
of pathogenic autoantibodies22. Findings from predictive software analyses (using the DNASTAR 
Jameson–Wolf method) suggest that the substitution His300Asp encoded by variant rs35771982 
gives rise to a PLA2R protein with a more ‘immunogenic’ secondary structure that may promote 
antibody production69. However, modelling of HLA–peptide complexes suggests that amino acid 
changes encoded by variants of PLA2R, at least in the context of HLA-DR3 and HLA-DR15, have 
little impact on their predicted presentation by HLA and that structural differences between HLA-DR 
molecules exert a greater influence19. Indeed, the dominant HLA-DQA1 SNP was more strongly 
associated with membranous nephropathy than the leading PLA2R SNP22. 
Clearly, identification of immunodominant PLA2R T cell epitopes and improved understanding of 
their interactions with HLA-DR and HLA-DQ would provide further insights into the pathogenesis 
of membranous nephropathy. Disease mechanisms in the context of PLA2R-negative idiopathic 
membranous nephropathy require investigation, and possible differences in disease pathogenesis 
between ethnic groups also warrant further consideration. Interestingly, commonalities exist in some 
of the HLA associations in anti-PLA2R membranous nephropathy and some ‘secondary’ causes of 
membranous nephropathy (see below). Whether these commonalities are related to immune 
mechanisms that favour subepithelial immunoglobulin deposition remains to be established. 
ANCA-associated vasculitis 
The ANCA-associated vasculitides are the most common cause of rapidly progressive 
glomerulonephritis. They can be divided into syndromically defined conditions: granulomatosis with 
polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic GPA (EGPA; also known as 
Churg–Strauss syndrome)74,75. The majority of people with GPA have ANCA specific for PR3 and a 
cytoplasmic ANCA (cANCA) pattern on imaging by indirect immunofluorescence, whereas most 
people with MPA, and 40% of individuals with EGPA, have ANCA specific for MPO with a 
perinuclear pattern of ANCA staining (pANCA). Approximately 10% of cases of GPA and MPA are 
ANCA-negative. The importance of including antigen specificities (that is, PR3 or MPO) in the 
description of clinical syndromes in AAV is supported by clear genetic differences between PR3-
AAV and MPO-AAV76. Early studies of HLA associations with AAV using serotyping were limited 
by the absence of patient stratification on the basis of ANCA specificity77,78. Molecular HLA typing, 
together with the use of antigen-specific stratification, has helped to define more specific 
associations of HLA with AAV, a full list of which can be found in Supplementary Table 3. 
The most consistent HLA association in PR3-AAV is with HLA-DP. The HLA-DPB1*04:01 allele, 
equating to the HLA-DPA1–HLA-DPB1 heterodimer known as HLA-DP4, was associated with an 
increased risk of PR3-AAV in three European studies (OR 3.38–5.27)79,80,81; by contrast, HLA-
DPB1*02:01 and HLA-DPB1*03:01 might be protective79,81. Patients with PR3-AAV who express 
HLA-DPB1*04:01 — particularly homozygotes — might be at higher risk of relapse than patients 
with other HLA alleles80. Three GWAS have shown strong links between PR3-AAV and SNPs in the 
HLA-DP region76,82,83. The strongest association is with the rs3117242 SNP in European patients 
with PR3-AAV76, an association that was replicated in a case–control study of Chinese patients with 
GPA (80% of whom were cANCA-positive)84. A 2013 GWAS mapped the most significant SNP to 
HLA-DPB1*0482, whereas a 2017 study identified positive associations between PR3-AAV and 
SNPs within the HLA-DPB1 region, including rs14153023383. A comparison of HLA-DP expression 
levels on B cells and monocytes from healthy donors carrying the risk allele (rs141530233) or 
protective allele (rs1042169) demonstrated that individuals who carried the risk allele had lower 
expression of HLA-DP than those who carried the protective allele. Furthermore, individuals with 
lower expression of HLA-DP had higher proportions of complementary PR3 (cPR3) peptide-specific 
CD4+T cells, suggesting that reduced HLA-DP expression results in decreased thymic deletion of 
these autoreactive T cells83. PR3-AAV has also been associated with other HLA-DR alleles 
(Supplementary Table 3). Of these, the most pronounced seems to be the risk effect of HLA-
DRB1*15 in African Americans, with HLA-DRB1*15:01 having the capacity to bind both PR3 and 
cPR3 peptides85. 
Compared with PR3-AAV, fewer HLA association studies have been performed for MPO-AAV, with 
the literature comprising several case–control studies in Asian populations (in which MPO-AAV is 
more common than PR3-AAV) and two GWAS in European cohorts. HLA-DRB1*09:01 is 
consistently and positively associated with MPO-AAV in Japanese populations86,87,88,89, whereas 
HLA-DRB1*11:01 conferred risk in a Chinese population90. GWAS have also shown association 
between MPO-AAV and HLA-DQ, including variants in HLA-DQA1 and HLA-DQB176,83; 
associations with variants in HLA-DQA2 have also been reported. 
The HLA associations in EGPA are distinct from those associated with MPO-AAV and PR3-AAV, 
providing a genetic basis for classifying EGPA as a separate disease entity. The HLA-DRB4 gene 
(which encodes the HLA-DRB4 chain and determines the HLA-DR53 serotype) was associated with 
an increased risk of EGPA in both genetic association studies dedicated to this disease91,92. 
Furthermore, a correlation was reported between HLA-DRB4 frequency and the number of vasculitic 
manifestations91. Positive associations with EGPA were specifically reported for HLA-DRB1*04 and 
HLA-DRB1*07, which are alleles in strong linkage disequilibrium with HLA-DRB491,92, whereas a 
protective effect was reported for HLA-DRB1*13 and HLA-DRB391,92. In light of the clear 
association between HLA-DP and PR3-AAV, Wieczorek et al. also examined HLA-DP alleles in 
EGPA but found no association92. 
Immunoglobulin A nephropathy and Henoch–Schönlein purpura 
Immunoglobulin A (IgA) nephropathy (IgAN) is the most common primary glomerulonephritis 
worldwide. IgAN is characterized by haematuria and histologically by mesangial proliferative 
glomerulonephritis with mesangial IgA deposition. A small proportion of patients present with acute, 
rapidly progressive glomerulonephritis. The pathogenesis of IgAN is thought to involve 
dysregulation of mucosal immunity, which facilitates the production of poorly glycosylated IgA1. 
The resultant galactose-deficient IgA1 acts as an autoantigen, leading to immune complex formation, 
deposition in the glomerular mesangium and glomerular injury93,94. 
Strong epidemiological evidence, including familial aggregation of cases and geographic variability 
in disease prevalence and phenotype95,96, supports a genetic basis for IgAN, although 
epidemiological studies have historically been hampered by the phenotypic heterogeneity of IgAN 
and potential inaccuracy in case ascertainment96. Early (serological) HLA association studies 
reported a number of different risk associations in both class I HLAs (for example, HLA-B27 and 
HLA-B35)97,98,99 and class II HLAs (that is, in HLA-DR1, HLA-DR4 and HLA-
DQ4)97,99,100,101,102,103,104,105. With the exception of HLA-DR4, which has been repeatedly observed in 
Japanese cohorts99,100,101,102,103,104, there was little uniformity in the findings. Supplementary 
Table 4 describes all reported HLA associations in IgAN. 
GWAS over the past 8 years have identified several susceptibility loci, of which the HLA region has 
emerged as the strongest signal106,107,108,109, with HLA-DQ being particularly important. Other non-
HLA genes within the MHC region are also associated with IgAN, including interferon-regulated 
genes involved in antigen degradation and processing107. In one study of patients of European 
ancestry with biopsy-proven IgAN, the strongest SNP associations were localized to HLA-DQ, with 
the imputed alleles HLA-DQB1*05:01 and HLA-DQB1*02:01 exerting risk and protective effects, 
respectively106. A combined GWAS of Han Chinese and European populations similarly localized 
the most significant SNPs to the HLA-DQB1 region, with HLA-DQB1*06:02 identified as a 
protective allele107. HLA-DQ associations were also identified in two subsequent GWAS: HLA-
DQB1*03:02 conferred risk of IgAN in Han Chinese patients109, whereas in a cohort of European 
and Han Chinese patients, Kiryluk et al. confirmed a protective effect of HLA-DQB1*02:01108.  The 
HLA-DQA1 locus has also been associated with IgAN and, similar to HLA-DQB1, seems to confer 
both risk (HLA-DQA1*01:01) and protective (HLA-DQA1*01:02) influences108,109. 
In light of the phenotypic heterogeneity of IgAN, HLA correlations have been examined in the 
context of stable and progressive disease, with varying results. In Japanese cohorts, HLA-DR4 has 
been linked with both disease progression102 and a favourable clinical course100. In a 1995 study, 
Raguenes et al. associated HLA-DQB1*03:01 with aggressive disease110; 9 years later, Kiryluk et al. 
reported the SNP rs7763262 (in the region of HLA-DQ and HLA-DR) to be associated with the 
greatest risk of progression108. Regarding insights into the pathogenesis of IgAN, geographical 
variations in HLA risk allele frequency are associated with local environmental risk factors for 
IgAN, such as helminth diversity108. This observation supports a disease model in which mucosal 
infection and inflammation contribute to the synthesis of poorly galactosylated IgA1 and the risk of 
subsequent autoimmunity is modulated by the HLA repertoire. 
Studies focusing on Henoch–Schönlein purpura (also known as IgA vasculitis) have uncovered a 
range of HLA associations, some of which overlap with those linked to IgAN. HLA-B35 was 
reported as conferring risk of Henoch–Schönlein purpura in Turkish111 and Han Chinese 
populations112 and has also been associated with IgAN in both European and Asian patients98,99. 
HLA-A11, a risk allele for Henoch–Schönlein purpura in Turkish and Mongolian cohorts, has also 
been linked to IgAN109. HLA-DRB1*01 is the most commonly reported class II HLA associated with 
Henoch–Schönlein purpura113,114,115, with HLA-DRB1*01:03 identified as the specific risk allele in a 
Spanish population115. A protective effect of HLA-DRB1*07 in Henoch–Schönlein purpura has also 
been repeatedly reported in European cohorts113,114,116. The HLA-DQ associations with IgAN have 
not, however, been described in Henoch–Schönlein purpura, potentially related to differences in the 
ethnicity of the cohorts studied. 
Lupus nephritis  
SLE is the prototypic multisystem autoimmune disease; it is characterized by a strong female 
predominance, complement activation and the presence of circulating and tissue-deposited immune 
complexes. The kidney is a major target in SLE, with lupus nephritis being a leading cause of 
morbidity and mortality. Considerable evidence supports a genetic component in SLE: although the 
majority of SLE heritability is attributed to non-HLA genes, important HLA associations have been 
identified117. For example, the HLA-DR3–HLA-DQ2, HLA-DR15(2)–HLA-DQ6(1) and HLA-DR8–
HLA-DQ4 haplotypes contribute to the risk of developing SLE. These risk haplotypes are 
approximately twice as common among patients with SLE as in healthy controls118. A sequencing 
analysis of the HLA region in patients with lupus nephritis and healthy controls119 identified several 
HLA risk variants associated with lupus nephritis, including amino acid variations in  HLA-DRB1 at 
position 11, HLA-DQB1 at position 45, HLA-DPB1 at position 76 and HLA-A at position 156. Other 
studies have compared HLA associations in patients with biopsy-proven lupus nephritis to those of 
patients with SLE without lupus nephritis. One study showed that HLA-DQB1 alleles in linkage 
disequilibrium with HLA-DR15 were predictive of lupus nephritis, whereas HLA-DR4 was 
protective120. In a multiethnic US cohort, HLA-DRB1*15:03 was a risk factor for new or worse 
proteinuria, whereas HLA-DRB1*02:01 was protective121,122; by contrast, in an Italian cohort, HLA-
DR3 conferred risk and HLA-DR15 and HLA-DQA1 alleles interacted in modulating risk or 
protection from lupus nephritis123. Interestingly, a study of patients with chronic kidney disease of 
various aetiologies found the rs2187668 SNP, which maps to HLA-DQA1 and confers a higher risk 
of membranous nephropathy, to also be over-represented in patients with lupus nephritis124. 
Meta-analyses have also examined HLA determinants in lupus nephritis susceptibility. One meta-
analysis of three GWAS that compared HLA associations in European women with SLE with and 
without lupus nephritis found an association of HLA-DR3 with lupus nephritis, with links to HLA-
DR15 falling short of statistical significance125. Another meta-analysis of case–control studies 
focused on HLA-DR in lupus nephritis126. The researchers identified a number of HLA-DR alleles 
associated with the risk of and protection from SLE and lupus nephritis, with the greatest magnitude 
of effects identified for HLA-DR3 and HLA-DR15 (as risk allomorphs) and HLA-DR4 and HLA-
DR11 (as protective allomorphs). 
HLA transgenic lupus-prone mice have provided mechanistic insights into HLA-mediated 
susceptibility and protection in lupus nephritis. A study of lupus-nephritis-prone NZM2328 mice 
engineered to express HLA-DR3 (HLA-DRB1*03:01) and deficient in mouse MHC class II showed 
they developed proteinuria at an earlier age than NZM2328 mice that expressed both HLA-DR3 and 
intact mouse MHC class II, with a higher proportion exhibiting renal wire loop, vasculitic and 
crescentic lesions127. Most patients with lupus nephritis have both anti-double-stranded DNA 
(dsDNA) and anti-Smith antigen (Sm) antibodies128; in this study, NZM2328.DR3-transgenic mice 
spontaneously developed both anti-dsDNA and anti-Sm antibodies only when deficient in murine 
MHC class II127. These findings suggest that mouse MHC class II alleles confer dominant resistance 
to the HLA-DR3-mediated development of anti-Sm autoantibodies in NZM2328 mice, possibly 
through the generation of anti-Sm-specific Treg cells, in a manner similar to that mediated by HLA-
DR1 in anti-GBM disease11. 
Tubulointerstitial nephritis and uveitis 
Tubulointerstitial nephritis and uveitis (TINU) is a rare syndrome characterized by the presence of 
both tubulointerstitial nephritis and uveitis, although some patients present with uveitis or  
tubulointerstitial nephritis alone. This syndrome is most commonly diagnosed in adolescents, and 
patients can present with impaired kidney function; the development of chronic kidney disease is not 
unknown. TINU is probably an autoimmune disease and tends to respond to corticosteroids. 
Histologically, it is characterized by tubulointerstitial oedema and a dense interstitial lymphocytic 
infiltrate, with some plasma cells and eosinophils. Documented HLA associations in TINU include 
the HLA-DRB1*01–HLA-DQA1*01–HLA-DQB1*05 haplotype (HLA-DR1–HLA-DQ5)129. Two 
studies in which patients underwent extended HLA-DR1 typing reported that the majority carried the 
HLA-DRB1*01:02 allele129,130. HLA typing of patients with only uveitis suggests that HLA-
DRB1*01:02 is particularly associated with the uveitis component of TINU130. In a Finnish cohort, 
the associations were somewhat different, with HLA-DQA1*04:01, HLA-DQB1*04:02 (HLA-DQ4) 
and HLA-DRB1*08 (HLA-DR8) being implicated131. 
HLA and other renal diseases 
In addition to autoimmune diseases, HLA types are also associated with susceptibility to various 
infectious diseases, probably by influencing the strength and direction of immune responses. For 
example, chronic hepatitis B infection, an ongoing major global health problem, is associated with 
HLA-DQ and HLA-DP allomorphs132. Furthermore, HLA associations have been described for 
kidney diseases that have traditionally been considered non-immune but are now recognized as 
having marked inflammatory components. The mechanisms that might underpin these HLA 
associations are unclear, assuming that the associations are not confounded by non-HLA genetic 
polymorphisms within the MHC region. 
Infection-related glomerulonephritis and sepsis-induced acute kidney injury 
Various infections can cause glomerulonephritis through the formation of in situ immune complexes 
in response to planted (or potentially endogenous) glomerular antigens, through T cell reactivity to 
these antigens and/or through the deposition of circulating immune complexes. Classical 
experimental studies suggest that the intensity and direction of the immune response helps determine 
the nature and severity of glomerular injury133. Cohorts of patients with biopsy-proven hepatitis-B-
associated membranous nephropathy suggest an increased frequency of HLA-DQB1*03:03 (HLA-
DQ9), HLA-DQB1*06:03 (HLA-DQ6) and HLA-DRB1*15:01 alleles, probably not related to an 
increased risk of chronic hepatitis B infection itself134,135,136. Interestingly the study that implicated 
HLA-DRB1*15:01 in hepatitis-B-associated membranous nephropathy also found HLA-
DRB1*15:02 to be associated with hepatitis-B-associated membranoproliferative 
glomerulonephritis137, consistent with subtle differences in HLA influencing immunity and thus the 
pattern of injury. With one possible exception138, studies have not shown an association between 
HLA class I molecules and hepatitis-B-related membranous nephropathy. 
Hepatitis C infection results in cryoglobulinaemic vasculitis in a minority of individuals, with a 
membranoproliferative pattern of glomerular involvement. Although HLA-DR3 has been implicated 
in hepatitis C-related cryoglobulinaemic vasculitis139, results have been inconsistent when comparing 
hepatitis C-infected individuals with and without cryoglobulinaemia. A GWAS found a potential 
association of HLA-DRB1 and/or HLA-DQA1 with hepatitis C-related cryoglobulinaemia but noted 
that the SNP was located in an intronic region of the MHC class III gene NOTCH4 140, potentially 
implicating this non-HLA gene in this complication of hepatitis C. 
Findings from studies of HLA associations with post-streptococcal glomerulonephritis (PSGN) have 
also been inconsistent. Associations with HLA-B12 (the serotype of the HLA-B44 and HLA-B45 
groups of alleles), HLA-DRB1*03, the HLA-DRB1*13:02–HLA-DQA1*01:02–HLA-DQB1*06:04 
haplotype and with alleles encoding HLA-DP5 have been described141,142,143. Although some of these 
studies were in paediatric populations, in whom PSGN is more likely to be a sole contributor to the 
glomerular lesion, the now recognized overlap between PSGN and C3 glomerulopathy has the 
potential to complicate these findings. Acute kidney injury (AKI) is a fairly common complication of 
systemic sepsis, resulting from effects of the pathogen itself or to the body’s response to infection. 
One study that examined the relationship between HLA-DR and AKI found no association in early 
AKI but reported that individuals with four HLA-DR alleles (that is, those individuals expressing 
two further HLA-DR alleles of HLA-DRB3, HLA-DRB4 or HLA-DRB5) had a higher risk of 
receiving early renal replacement therapy than those who expressed fewer than four HLA-DR 
alleles144. 
Minimal change disease and primary focal and segmental glomerulosclerosis 
Minimal change disease (MCD) and primary focal and segmental glomerulosclerosis (FSGS) are 
characterized by heavy proteinuria, with evidence of both immune dysfunction and podocyte 
vulnerability. Most cases of adult disease are biopsy proven, whereas in children the conditions are 
defined syndromically according to their responsiveness to corticosteroids. Studies of HLA in 
paediatric patients with steroid-sensitive nephrotic syndrome (SSNS) date back to 1980, with the 
identification of HLA-DR7 as a risk factor145,146 — a finding that was supported by further studies147. 
Other studies of SSNS have identified an association with HLA-DQ148 and with HLA-DQ2 149, 
whereas HLA-DR2 (HLA-DR15–HLA-DR51) might be protective147. The largest GWAS of 
childhood SSNS150 identified a significant association at the HLA-DQA1 locus; the strongest 
associations involved missense variants that resulted in impaired or aberrant HLA-DQ assembly, 
leading to the hypothesis that antigen presentation might in some way be impaired151. Another 
potentially important finding in that study was the presence of rare variants in PLCG2, which 
encodes phospholipase Cγ2, a signalling molecule that is found both in T cells152 and in cells with 
high MHC class II expression, including dendritic cells and B cells153,154. Of interest, 
abnormal PLCG2 function is associated with immune abnormalities in both humans and 
mice154,155,156. Defining the functional relationship between HLA-DQ and PLCG2 may help elucidate 
the mechanisms that underpin immune dysregulation in SSNS. 
Alport syndrome 
Mutations in genes encoding the α3, α4 or α5 chain of collagen IV disrupt the  formation of α3α4α5 
trimers, giving rise to Alport syndrome and thin basement membrane nephropathy42. Alport 
syndrome is characterized by haematuria, proteinuria, progressive renal impairment, sensorineural 
deafness and ocular abnormalities. Most cases of Alport syndrome arise from X-linked inheritance 
of COL4A5 mutations, with other cases resulting from autosomal inheritance of mutations 
in COL4A3 and COL4A4 on chromosome 242. Two groups have evaluated HLA in Alport syndrome 
and found associations with HLA-DR2 and HLA-DRB1*16157,158. However, the underlying 
mechanism for HLA associations in this essentially non-immune disease remains unexplained. 
Diabetic kidney disease 
Diabetic kidney disease (DKD) is associated with the autoimmune disease T1DM or the metabolic 
disease type 2 diabetes mellitus (T2DM) and is one of the most common causes of renal disease 
worldwide. T1DM has clear HLA associations38, and in comparisons with healthy populations, HLA 
risk alleles for T1DM are likely to also be present in patients with T1DM-associated DKD. Some 
studies have found no relationship between HLA and the risk of diabetic complications159,160. Other 
reports, some of which controlled for disease duration and focusing on the HLA-DR3 and HLA-DR4 
allomorphs a priori, have implicated them variably as susceptibility or protective factors in overt 
DKD or microalbuminuria161,162,163,164. In a large, phenome-wide association study (PheWAS), the 
HLA-DRB1*04 and HLA-DQB1*03:02 alleles, found in the HLA-DR4–HLA-DQ8(3) risk 
haplotype, were associated with both T1DM itself and DKD163. However, when compared with the 
presence of the disease itself, the odds ratio for both HLA-DQ8 and HLA-DR4 was substantially 
higher for both acute and chronic complications of T1DM, suggesting that disease severity, age of 
onset or disease duration contribute to the association of these HLAs with DKD. HLA-A2 has been 
associated with the development of microalbuminuria in T1DM165. HLA associations have been 
variably reported with DKD in patients with T2DM. Indigenous Canadians with T2DM who carry 
HLA-A2 with either HLA-DR4 or HLA-DR8 develop ESRD at a younger age than those who carry 
other HLA types, possibly reflecting differences in the severity or age of onset of T2DM166. In a 
Mexican population with T2DM, HLA-DRB1*15:02 was associated with DKD, and in an American 
Indigenous population with T2DM, the HLA-DRB1*04:07 allele was associated with protection167. 
HLA-DQB1*05:01 may be protective in Han Chinese with T2DM168. These findings highlight some 
of the complexity in assessing the potential role of HLA in DKD, with contributions from ethnicity 
and, in the case of T1DM, the autoimmune basis of the underlying disease. Further complicating 
analyses of HLA in DKD is the role of proteins that exist in linkage disequilibrium with HLA. Many 
of these proteins, including RAGE and TNF, are also associated with complications of diabetes 
mellitus, including DKD169. 
Drug-induced renal disease 
ADRs are relevant to the kidney in terms of being a target of drug-induced damage and in mediating 
the toxic effects of drugs such as allopurinol. Although type A ADRs can be predicted on the basis of 
the drug’s mechanism of action, type B ADRs are idiosyncratic. Type B ADRs are often immune -
mediated, often in a CD8+ or CD4+ cell-mediated, delayed type hypersensitivity-like manner. An 
increasing body of evidence indicates that HLA molecules are not only associated with type B ADRs 
but are also involved mechanistically170. 
Indeed, HLA allotypes have been directly implicated in a number of ADRs. A broad array of HLA–
drug associations exist across HLA class I and HLA class II molecules, involving many commonly 
prescribed drugs and antibiotics. A number of theories have been postulated to explain the 
mechanisms underlying these HLA–drug associations, including direct haptenation of the drug to the 
peptide–HLA complex, as well as the ‘p-i concept’, in which the drug bridges the interface between 
the TCR and peptide–MHC complex, thereby activating T cells bearing TCRs that would ordinarily 
be non-reactive170. Arguably, the best understood example of HLA involvement in ADRs is the 
association of HLA-B*57:01 with hypersensitivity reactions in patients taking the anti-retroviral drug 
abacavir. Abacavir sits deep within the carboxy-terminal end of the antigen-binding cleft of the 
HLA-B*57:01 molecule, thereby altering the repertoire of self-peptides that this HLA molecule 
presents49. The co-binding of abacavir, with the consequent altered self-peptide repertoire presented 
by HLA-B*57:01 in essence creates an ‘altered self’, resulting in the ensuing peptide–drug–HLA 
complex being identified as foreign and inducing an ADR. This association was very specific for 
HLA-B*57:01, as very closely related HLA allomorphs, including HLA-B*57:03 (which differ only 
by a few residues), were incapable of binding abacavir49. Accordingly, tissue typing for HLA-
B*57:01 is now recommended for individuals with HIV infection being considered for abacavir 
therapy. However, more work is required to understand the mechanistic bases underpinning other 
HLA–drug associations. 
Beyond abacavir, reports from the past couple of years have implicated other drugs (such as 
doxofylline)171, drug-like molecules (such as 3-formylsalicylic acid and 2-hydroxy-1-
naphthaldehyde)171 and contact sensitizers (such as urushiol and house dust mite-derived 
phospholipase)172,173 in association with MHC class I-like molecules, including those of the CD1 and 
MHC class I-related gene protein (MR1) family, which present lipids and vitamin B metabolites, 
respectively, to other types of T cells, including innate-like NK T cells and mucosal-associated 
invariant T cells. However, this area of research is very germinal and requires further investigation.  
The mechanism of HLA associations with drug-induced kidney disease is currently unknown; 
however, HLA associations for type B ADRs exist for a number of drugs that induce immune-
mediated kidney injury, including allopurinol, sulfonamides, nonsteroidal anti -inflammatory drugs 
(NSAIDs), penicillins, penicillamine and gold sodium thiomalate170. The association between 
allopurinol hypersensitivity and HLA-B*58:01 was initially identified in a Han Chinese 
population174 and subsequently confirmed as having a gene dosage effect in other ethnicities175. 
Interestingly the risk of severe reactions is increased in individuals with renal impairment. CD8+ T 
cells from HLA-B*58:01-positive individuals respond to allopurinol in vitro, regardless of whether 
the T cells were derived from individuals with allopurinol hypersensitivity or allopurinol -naive 
patients176. Interestingly, compared with allopurinol, T cell responses were stronger to oxypurinol, 
which is the major allopurinol metabolite176,177 that accumulates in patients with renal impairment, 
suggesting a mechanistic link between kidney disease itself and HLA-mediated drug toxicity. 
HLAs are also associated with the development of drug-induced kidney injury. For example, 
penicillins and penicillamine can haptenate endogenous proteins. The association of penicillin with 
interstitial nephritis has been linked to HLA-A2 and HLA-DR52, whereas the association of 
penicillamine with membranous nephropathy and, less commonly, with AAV has been linked to 
HLA-B8, HLA-DR1 and HLA-DR3170,178,179. Gold sodium thiomalate also causes membranous 
nephropathy and is similarly associated with HLA-B8, HLA-DR1 and HLA-DR3 as well as with 
HLA-DQA1*0501180,181; interestingly, some of these associations have been reported in patients with 
‘primary’ anti-PLA2R-mediated membranous nephropathy. 
HLA and disease-independent risk of ESRD 
Several reports have examined possible associations between HLA types and ESRD182,183,184. Most of 
these studies have studied waitlisted candidates for renal transplantation in fairly homogeneous 
ethnic populations. Although underpowered, most of these studies have not defined significant 
associations and to date no consistent HLA associations with ESRD itself have been identified. Of 
note, studies of the association of HLA types with ESRD might be confounded by the presence of 
HLA associations with individual diseases. In addition to describing associations between the HLA-
DRB1*04 and HLA-DQB1*03:02 alleles and DKD, the large PheWAS discussed earlier also 
reported an association between HLA-DQB1*03:02 and kidney transplantation (OR 1.4), which was 
potentially related to the increased risk of T1DM and DKD (OR 7.1) observed for this allele 163. Some 
reports suggest that some HLA types can affect the severity of kidney disease or risk of progression 
independent of disease aetiology. Although this hypothesis remains to be adequately tested, our 
current understanding of the mechanisms of HLA and of disease progression suggest that it is the 
influence of HLA on the individual underlying conditions causing kidney disease that mediates its 
involvement in progressive renal disease. Nonetheless, particular HLA types could promote, for 
example, a more generalized pro-fibrogenic T cell phenotype, which might contribute to disease 
onset or disease progression. 
CONCLUSIONS 
The development and evolution of genetic and molecular typing technologies and better case 
ascertainment has enabled detailed examination and in many cases definition of HLA associations in 
a variety of kidney diseases. The field continues to evolve, both with the recognition of epistasis 
between variants of autoantigens and HLA, and with growing understanding of the mechanisms that 
underpin the associations between HLA and disease. These findings have several implications that 
are highly relevant to disease. Some autoimmune renal diseases have characteristics that render them 
suitable archetypal autoimmune diseases for the study of HLA, having the potential to define 
fundamental disease biology with wide applicability. In diseases in which pathogenesis remains 
uncertain (for example, MCD), discoveries in the HLA field might help define disease mechanisms. 
Insights from HLA studies can also aid disease diagnosis and classification (for example, by 
strengthening the notion that PR3-AAV and MPO-AAV are distinct entities on the basis of their 
different HLA associations). HLA-based identification of subgroups of individuals at risk of disease 
progression might therefore in the future form part of risk stratification algorithms. 
Arguably the most important area of disease management that would be affected by greater 
mechanistic understanding of the relationships between susceptibility and protective HLA 
allomorphs is in the development of new and more targeted therapies. Current treatments for immune 
kidney disease are not only of limited efficacy but also lack specificity, being associated with 
substantial immune and metabolic adverse effects. Improved understanding of the relationships 
between the TCR, HLA and the process of antigen presentation and recognition at a peptide and 
structural level will aid in the development of new tolerogenic therapies, including peptide 
immunotherapies, peptide complexed nanoparticles and cell therapy using antigen and peptide-
specific Treg cells. Such treatments, especially when combined judiciously with conventional or new 
anti-inflammatory agents, have the potential to restore tolerance and perhaps even effect a cure. The 
field of HLA biology in kidney disease progressed substantially from the first description of the 
association of HLA allomorphs with renal disease. The future promises much, with the evolution of 
understanding not only of HLA itself but also of its relationship with antigenic peptide and, more 
crucially, the responses via the TCR of the responding T cells 
 
  
KEY POINTS 
 The HLA, which is the most polymorphic region of the human genome, is 
associated with various kidney diseases; some of these diseases are immune-
mediated whereas in others the pathogenesis is uncertain or the relevance of HLA 
is less clear. 
 Advances in molecular techniques and the use of model systems have helped define 
the mechanistic basis of HLA associations and in some instances have epistatically 
linked HLA to other genes. 
 The characteristics of some renal diseases potentially enable them to serve as 
archetypes for the study of HLA associations in other conditions. 
 Exactly how HLA facilitates the development of immune kidney diseases at the 
level of HLA–peptide–T cell receptor interactions is a fundamental research 
question; mechanistic insights will have clear translational implications for the 
development of more targeted therapies. 
 
GLOSSARY 
Self-peptides 
Peptides derived from endogenous (host) proteins that are often displayed on HLA class I and II.  
CD8+ T cells 
T cells that recognize peptide–HLA class I complexes. When activated, they can induce target cell death and produce  
pro-inflammatory cytokines. 
CD4+ T cells 
T cells that recognize peptide–HLA class II complexes. They direct immune responses as T helper cells or maintain 
tolerance and regulate responses as T reg cells. 
Non-self-peptides 
Peptides derived from foreign proteins, such as microbial pathogens, that are often displayed on HLA class  I and II. 
Polymorphisms 
A polymorphism is a DNA sequence variation within an allele that can result in a different gene product.  
Haplotype 
A group of alleles on the same chromosome that are commonly inherited as a unit.  
Linkage disequilibrium 
The non-random association of alleles at two different loci, such that the observed population frequency of the allele 
combination exceeds that expected by chance. 
8.1 ancestral haplotype 
Also known as the HLA-A1-B8-DR3-DQ2 haplotype, the 8.1 ancestral haplotype is common in European populations, 
most likely owing to common ancestral descent inherited in linkage disequilibrium.  
Clonotypic 
In the context of the TCR, a clonotype describes the unique combination of nucleotide sequences that exists after gene 
rearrangement. 
Allomorph 
The unique HLA molecule arising from one (class I) or two (class II) particular alleles.  
Variable domain 
The αβ TCR is made up of α and β-chains each with constant and variable domains. With genetic recombination, the 
variable domain is highly diverse, ensuring a very broad repertoire of different TCRs.  
T cell cross reactivity 
The capacity of a T cell, via its TCR, to recognize more than one peptide–MHC complex. 
Alloreactivity 
Cellular or humoral reactivity to antigens (for example, HLA) not present in the particular individual but expressed by 
other individuals of the species. 
Biased TCR usage 
A phenomenon whereby, despite the diversity of the TCR repertoire, there is preferential use of a limited number of TCRs 
in an immune response. 
Dominantly protective allele 
An HLA allele that confers protection from the specified disease even in the presence of a co -inherited risk allele. 
Epitope spreading 
The broadening of an immune response involving reactivity not only to the initial focused epitope but also to other 
epitopes on the same or a different protein. 
Peptide-binding register 
The particular amino acid sequence of a peptide that binds to the peptide-binding groove of the MHC. 
Immunodominant peptide epitopes 
T cell responses are usually specific for one or only a few epitopes within a particular antigen, referred to as 
immunodominant. 
Epitope capture 
A process whereby a high-affinity peptide that binds to one HLA molecule preferentially, effectively limits the binding to 
another HLA allomorph with a lower affinity for the same or a similar peptide.  
Shared epitope 
Refers to a sequence motif at amino acids 70–74 of the HLA-DR chain that is shared by HLA alleles implicated in 
rheumatoid arthritis and found in the majority of individuals with this disease.  
Citrullination 
The post-translational modification of proteins via the conversion of arginine to citrulline. Reac tivity to these altered self-
proteins is common in rheumatoid arthritis. 
Epistasis 
Interactions between different genetic loci that potentially affect phenotype in health or disease.  
Molecular mimicry 
A phenomenon whereby a pathogen-derived peptide sufficiently similar to a self-peptide can induce loss of tolerance. 
Type B adverse drug reactions 
(ADRs). Type B ADRs are less common than type A ADRs, tend to be idiosyncratic and unpredictable and are often 
immune-mediated. 
DNASTAR Jameson–Wolf method 
A computer algorithm that uses a primary amino acid sequence to predict the structural features of a protein and its 
potential antigenic determinants. 
Phenome-wide association study 
(PheWAS). A study that examines the effects of one or a limited number of genetic variants in multiple phenotypes. 
Type A ADRs 
Type A ADRs can be predicted on the basis of the drug’s pharmacological properties and mechanism of action.  
Delayed type hypersensitivity 
A cell-mediated effector immune response, occurring 24 hours to several days after antigen re-exposure. 
Haptenation 
The process whereby a small molecule (hapten) such as a drug or drug metabolite binds covalently to an endogenous 
peptide or protein that is itself not usually antigenic. The resultant complex can elicit an immune  response. 
P-i concept 
The p-i (or ‘pharmacological interaction with immune receptors’) concept describes a non -covalent, reversible interaction 
between a drug and the MHC at the surface of an immune cell.  
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Figure 1 
 
a | A simplified diagram of the human major histocompatibility complex (MHC) locus, 
focusing on HLA loci known to be directly involved in antigen presentation, with 
examples of non-classical HLA gene loci and class III genes.  
b | Basic format of HLA class I and class II complexes. The class I HLA-A, HLA-B and 
HLA-C molecules consist of three α-chains encoded by one allele and complexed with β2-
microglobulin. The peptide-binding groove is formed by the α1 and α2 chains, and the 
molecule is anchored to the cell membrane by the α3 chain. The class II HLA-DR, HLA-
DQ and HLA-DP molecules are heterodimers of two α-chains encoded by one allele and 
two β-chains by another. The peptide-binding groove is formed by the α1 and β1 chains.  
c | Examples of the structures of complexes comprising the MHC class I and peptide; 
MHC class II and peptide; CD8+ T cell receptor (TCR), peptide and MHC class I; and 
CD4+ TCR, peptide and MHC class II. The view from above shows the peptide binding in 
the peptide-binding pockets in the groove formed by the α1 and α2 chains (class I) and α1 
and β1 chains (class II). The side views depict HLA–peptide complexes with TCRs 
contacting the landscape formed by the composite of HLA surface residues and outwardly 
oriented regions of the peptide. The TCR contacts are formed by hypervariable 
complementarity-determining regions with the variable domains of the TCRα and TCRβ 
chains. Structures for HLA class I molecules were defined by MacDonald et al.187 and for 
HLA class II by Broughton et al.188.  
d | Simplified basic HLA nomenclature using HLA-DR15 as an example. The simplest 
terminology describes HLA types determined by serology. Molecular typing allows the 
allele group and particular protein to be specified and extended descriptors indicate 
synonymous variants (that is, variants that do not result in a change in the amino acid 
sequence) and documentation of changes in non-coding regions. The letters at the end of 
the final field that indicate changes in expression are not depicted. C-ter, carboxyl 
terminus; HSP70, heat shock protein 70; N-ter, amino terminus; pMHC, peptide MHC; 
TNF, tumour necrosis factor.  
Part c courtesy of J. Petersen, Monash University, Australia. 
  
Figure 2 
 
 
a | Interactions between peptide–HLA complexes on thymic epithelial cells and dendritic 
cells (DCs) and T cell receptors (TCRs) define the T cell repertoire via positive and 
negative selection of T cells in the thymus.  
b | HLAs within secondary lymphoid organs, such as the spleen (shown as an example) 
and lymph nodes, maintain tolerance but also induce autoreactive T cell responses. In 
addition to mediating the generation of effector CD4+ T cells, HLA class II molecules are 
critical for autoantibody formation by generating T follicular helper (TFH) cells. These T 
cells promote the activation of antigen-specific autoreactive B cells. Tconv cell, 
conventional T cell; TH1 cell, T helper 1 cell; TH17 cell, T helper 17 cell; Tregcell, 
regulatory T cell 
  
Figure 3 
 
 
The expression of HLA class II is complex and varies between the glomerulus and the 
tubulointerstitium and in normal and inflammatory states.  
a | In health, a network of HLA class II-expressing interstitial dendritic cells (DCs) and 
macrophages survey the environment and have a number of roles, including presentation 
of filtered self-peptides to help maintain tolerance. In the glomerulus, HLA class II 
expression is less prominent, with some expression on intrinsic glomerular cells and on 
patrolling monocytes as well as intravascular B cells (not shown). DCs are rare in normal 
glomeruli.  
b | In severe glomerular disease, HLA class II is upregulated on intrinsic renal cells and 
infiltrating mononuclear phagocytes, with HLA class II expressed on intravascular 
monocytes mediating antigen-specific effector CD4+ cell activation. In the diseased 
interstitium, a variety of HLA class II-expressing cells may be important. Recruited 
monocytes differentiate into HLA class II-expressing inflammatory DCs and macrophages, 
B cells form aggregates and present their own antigen effectively to CD4+ T cells and 
tubular cells may acquire a pro-inflammatory phenotype. HLA class I is ubiquitously 
expressed by nucleated cells and mediates the local cytotoxic and pro-inflammatory effects 
of CD8+ T cells (not shown). BCR, B cell receptor; TCR, T cell receptor; Treg cell, 
regulatory T cell. 
  
Figure 4 
  
 
Positive and negative selection in the thymus, mediated by thymic epithelial cells and 
dendritic cells, results in T cell repertoires that are shaped by interactions between HLA–
self-peptide complexes and T cell receptors (TCRs).  
a | The immunodominant CD4+ T cell epitope in Goodpasture disease, α3135–145, binds to 
the risk HLA-DR15 and dominantly protective HLA-DR1 allomorphs in different 
registers, resulting in the preferential generation of conventional T (Tconv) cells in the 
context of HLA-DR15 and regulatory T (Treg) cells by HLA-DR1. In the context of the 
other genetic and environmental factors that cause Goodpasture disease, HLA-
DR15+ humans and transgenic mice are at risk of activation, expansion and differentiation 
of α3135–145-specific Tconv cells into T follicular helper (TFH) cells and T helper 1 (TH1) and 
17 (TH17) cells, which are essential for autoantibody production and serve to effect injury 
locally in the kidney. In humans and mice expressing HLA-DR1, antigen-specific 
Treg cells react with HLA-DR1 α3135–145 and dominantly protect those with HLA-DR15 
from developing disease.  
b | In abacavir-induced hypersensitivity syndrome, abacavir binds specifically to the 
peptide-binding groove of HLA-B*57:01, altering how self-peptides are presented by 
HLA-B*57:01 and converting some non-self-reactive CD8+ T cells to cells with 
‘autoreactive’ TCRs. CD8+ T cells acquire effector functions and mediate abacavir 
hypersensitivity syndrome. MHC, major histocompatibility complex. 
 
 
 
Table 1 :  Conventional HLA types and their characteristics 
 
HLA type Structure Serological nomenclature Other features 
HLA class I: HLA–peptide complexes that bind to CD8+ T cells 
HLA-A 
Heterodimer: β2-microglobulin with 
highly polymorphic α-chain; the α-
chain encompasses the peptide-
binding cleft and potential T cell 
receptor contacts 
In most cases, serological numbering tends to equate to 
allelic nomenclature 
None 
HLA-B As for HLA-A 
In most cases, serological numbering tends to equate to 
allelic nomenclature 
Some HLA-B serotypes are listed as 
‘Bw’, referring to shared motifs (eplets) 
that are recognized by alloantibodies 
HLA-C As for HLA-A 
Listed as ‘Cw’ to avoid confusion with complement 
components and other proteins 
None 
HLA class II: HLA–peptide complexes that bind to CD4+ T cells 
HLA-DR 
Invariant α-chain that forms the 
peptide-binding cleft with the highly 
polymorphic β-chain 
Serology largely, but not always, follows β-chain 
nomenclature (in the case of the HLA-DRB1 chain that 
is always present); HLA-DRB3, HLA-DRB4 and HLA-
DRB5 are represented by serologically defined HLA-
DR52, HLA-DR53 and HLA-DR51, respectively 
Some haplotypes include a further 
HLA-DR type encoded by an HLA-
DRB3, HLA-DRB4 or HLA-DRB5 
chain, often expressed at lower levels 
HLA-DQ 
Heterodimer: formed by polymorphic 
α-chains and β-chains 
Serological nomenclature usually references the β-chain; 
some β-chains form functional HLA proteins with more 
than one different α-chain, resulting in serological 
subtypes (for example, HLA-DQ2.2, HLA-DQ2.3 and 
HLA-DQ2.5) 
Strong linkage disequilibrium between 
HLA-DR and HLA-DQ regions 
HLA-DP 
Heterodimer: formed by polymorphic 
α-chains and β-chains 
Serological nomenclature usually references the β-chain 
Less strong linkage disequilibrium with 
other HLA components owing to 
position nearer the centromere and 
recombination hot spot between HLA-
DQ and HLA-DP 
Table 2:  Key HLA associations with kidney disease 
Locus and/or 
allele 
Serological 
equivalent 
Previous equivalents Disease Nature of 
association 
Refs 
HLA class I 
HLA-A2 HLA-A2 NA 
Diabetic nephropathy Risk (+) 165, 166 
Penicillin-associated AIN Risk (++) 170  
HLA-A*11:01 HLA-A11 NA IgAN Risk (+) 109  
HLA-B8 HLA-B8 NA 
Penicillamine and/or gold-associated 
membranous nephropathyb 
Risk (++) 181, 189 
HLA-B35 HLA-B35 NA IgAN and Henoch–Schönlein purpura Risk (+) 99  
HLA-DR 
HLA-
DRB1*01:01 
HLA-DR1 HLA-DRw1 Goodpasture disease 
Dominant 
protection 
16, 52 
HLA-
DRB1*01:02 
HLA-DR1 HLA-DRw1 TINU Risk (+) 129, 130 
HLA-DR3 HLA-DR3 HLA-DRw3 
Penicillamine or gold-associated 
membranous nephropathy 
Risk (++) 180, 181, 189 
HLA-
DRB1*03:01 
HLA-DR17(3) HLA-DR3 
Lupus nephritis Risk (++) 119  
Membranous nephropathy Risk (+++) 19, 21, 190, 191 
HLA-DRB1*04 HLA-DR4 HLA-DRw4 
Diabetic nephropathy Risk (++) 163, 166, 167 
IgAN Risk (++) 
99,100,101,102,103,–
104, 192 
Goodpasture disease Risk (+) 16, 18, 54 
HLA-DR7 HLA-DR7 HLA-DRw6 Steroid-sensitive nephrotic syndrome Risk (+) 139,140,– 141 
HLA-
DRB1*07:01 
HLA-DR7 HLA-DRw6 Goodpasture disease 
Dominant 
protection 
16, 52, 53 
Locus and/or 
allele 
Serological 
equivalent 
Previous equivalents Disease Nature of 
association 
Refs 
HLA-
DRB1*09:01 
HLA-DR9 
HLA-DRw9 MPO-AAV Risk (+) 86,87,88,– 89 
HLA-DRw9 Goodpasture disease Protection 55  
HLA-
DRB1*11:01 
HLA-DR11(5) HLA-DR5 MPO-AAV Risk (+) 89, 90 
HLA-DRB1*15 HLA-DR15(2) 
HLA-DR2b and HLA-
Dw2 
Lupus nephritis Risk (+) 122  
HLA-DRB1*15 HLA-DR15(2) 
HLA-DR2b and HLA-
Dw2 
PR3-AAV Risk (++) 85  
HLA-
DRB1*15:01 
HLA-DR15(2) 
HLA-DR2b and HLA-
Dw2 
Goodpasture disease Risk (+++) 
16,17,– 18, 52,53,54,–
55, 57, 193 
Membranous nephropathy (including 
hepatitis-B-associated) 
Risk (++) 19, 20, 137, 194 
HLA-DQ 
HLA-DQA1 NA NA 
Lupus nephritis Risk (+) 123  
MCD or FSGS Risk (+) 148, 150 
HLA-
DQA1*05:01c 
HLA-DQ5(1) HLA-DQ1 
Membranous nephropathy Risk (++) 21, 22, 67,68,69,– 70,190 
Penicillamine or gold-associated 
membranous nephropathy 
Risk (++) 180  
HLA-DQA2d NA NA MPO-AAV Risk (+) 76, 83 
HLA-DQB1 NA NA MPO-AAV Risk (+) 83, 88 
HLA-
DQB1*02:01 
HLA-DQ2 HLA-DQB2 Membranous nephropathy Risk (++) 21, 190 
HLA-
DQB1*03:01 
HLA-DQ7(3) 
HLA-DQw7 and HLA-
DQ3 
IgAN Risk (++) 108, 195, 196 
HLA-
DQB1*03:02 
HLA-DQ8(3) HLA-DQ3 Diabetic nephropathy Risk (++) 163  
Locus and/or 
allele 
Serological 
equivalent 
Previous equivalents Disease Nature of 
association 
Refs 
HLA-DP 
HLA-DPA1 NA NA IgAN Protection 107  
HLA-
DPB1*04:01e 
HLA-DPw4 
HLA-DPB4.1 and 
HLA-DPw4a 
Goodpasture disease Protection 56  
PR3-AAV Risk (+++) 79,80,– 81, 83, 84 
 
1. AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis; AIN, allergic interstitial nephritis; FSGS, focal and segmental 
 glomerulosclerosis; IgAN, immunoglobulin A nephropathy; MCD, minimal change disease; MPO, myeloperoxidase; NA, not 
 applicable; PR3, proteinase 3; TINU, tubulointerstitial nephritis and uveitis.  
 
2. aRisk effects categorized as + to +++ estimated on the basis of number and size of studies, consistency of association, odds ratio and 
 mechanistic explanation. bMembranous nephropathy is ‘primary’ anti-PLA2R (secretory phospholipase A2 receptor)-antibody-
 positive membranous nephropathy unless otherwise stated. 
 
3. cStudies denoting specific association with HLA-DQA1*05:01 are21,180,190; other studies quoted localize only to HLA-DQA1. 
 
4. dMerkel et al. 201783 localizes to HLA-DQA2 and Lyons et al. 201276 only to HLA-DQ. 
 
5. eStudies denoting specific association with HLA-DPB1*04:01 are56,79,80,81; Merkel et al. 201783 and Wu et al. 201784 localize only to 
 HLA-DPB. 
 
BOX 1  
HLA TYPING METHODS AND NOMENCLATURE 
 
Understanding HLA nomenclature and typing methods is important in interpreting studies of the 
association between HLA and kidney disease, particularly given that HLA typing methods have 
evolved substantially over the past few years. Progress has in part been driven by the transplantation 
field. Here, the potential antigenicity of polymorphisms throughout the HLA molecule is relevant as 
the HLA allomorphs themselves serve as alloantigens. This contrasts with autoimmunity, in which 
HLA polymorphisms in the peptide-binding groove and in potential T cell receptor contacts are most 
relevant. Information on HLA nomenclature, alleles and proteins can be accessed via the IPD-
IMGT/HLA database and at HLA alleles, proteins and nomenclature185. A brief description of the main 
HLA typing methodologies are outlined as follows. 
 
HLA serotyping 
Serotyping was the first method of HLA typing and uses antibodies that recognize HLA complexes on 
the cell surface. Improvements in serotype definitions over time resulted in nomenclature changes. For 
example, HLA-DQ1 was ‘split’ into two serotypes, HLA-DQ5 and HLA-DQ6. 
 
HLA haplotypes 
Linkage disequilibrium within the HLA region (excluding HLA-DP) results in the generation of 
haplotypes that are common among populations. An example of this is the so-called 8.1 ancestral 
haplotype, which includes HLA-A1, HLA-Cw7, HLA-B8, HLA-DR17(3), HLA-DR52 and HLA-
DQ2. This strong linkage disequilibrium in the HLA region can complicate analyses of disease 
susceptibility (for example, in defining associations between HLA-DR and HLA-DQ). 
 
PCR-based identification 
A variety of PCR-based methods have been developed using probes that can identify specific HLA 
types with varying resolution. With the advent of the molecular characterization of HLA alleles, the 
nomenclature evolved to reflect the individual α-chains for HLA class I molecules (and both α-chains 
and β-chains for HLA class II molecules) and the increasing number of alleles that were being defined. 
 
Genome-wide association studies (GWAS) 
Single nucleotide polymorphism (SNP) array data spanning the whole genome are used to impute 
individual HLA types (or regions) via SNPs situated close to HLA allelic regions. Some studies have 
confirmed HLA associations by targeted PCR-based HLA-based typing. GWAS databases exist that 
can be interrogated for HLA alleles and disease (for example, the GWAS catalogue). 
 
Phenome-wide association studies (PheWAS) 
PheWAS use similar SNP and imputation techniques to GWAS but examine the effects of one or a 
limited number of variants in multiple phenotypes (see, for example, PheWAS resources). 
 
Next-generation sequencing (NGS), including whole exome (WES) or whole genome 
sequencing (WGS) 
NGS, involving parallel sequencing of millions of small DNA fragments, enables rapid HLA class I 
and class II typing, including the identification of rare variants. These techniques, often performed as 
part of WES (involving sequencing of all the coding regions of DNA) or WGS (involving sequencing 
of the complete genome), are becoming established approaches to determine the HLA allelic makeup 
of an individual. 
 
BOX 2  
METHODOLOGIES FOR DISSECTING MECHANISMS OF HLA INVOLVEMENT IN 
DISEASE 
 
Peptide display 
Intracellular processing of antigens generates a limited number of peptide sequences. Given that an 
individual HLA allomorph does not bind every peptide that is generated, it is important to identify 
HLA–peptide pairings to investigate association with disease. Although predictive algorithms such 
as those used by the Immune Epitope Database are useful, it is now possible to identify and 
quantify the peptidome presented by different HLA types, for example, using unbiased assessment 
of HLA-bound peptides by mass spectrometry186 as described in the Systemic Atlas. 
 
HLA–peptide tetramers and multimers 
Although critically important in immune responses, antigen-specific T cells exist at low frequencies 
and can be difficult to identify. Conventional flow cytometry reagents will not identify antigen-
specific T cells; however, multimeric clusters of HLA–peptide complexes generated using 
fluorochrome-labelled HLA have increased binding avidity to T cell receptors (TCRs), meaning 
that T cells as rare as 1–5 per million can be identified, phenotyped and isolated. HLA class I–
peptide multimers are readily available; HLA class II–peptide multimers are more difficult to 
synthesize and are not as widely available. 
 
Structural biology 
If immunodominant T cell epitopes are known or suspected, modelling can be used to suggest 
peptide–major histocompatibility complex (MHC) structures. However, crystallography is needed 
to accurately and definitively determine the structure of HLA–peptide–TCR complexes. 
 
HLA transgenic humanized mice 
These humanized mice carry HLA molecules (class II or class I), usually of a single type and replacing 
the binding component of the corresponding mouse MHC molecules at a minimum. The selection of 
CD4+ or CD8+ T cells and activation of the corresponding T cell repertoire is therefore determined 
by interactions between HLA and mouse peptides. If mouse and human antigens are homologous 
(for example, in the case of α3 chain of type IV collagen), the system can be used to discover 
immunodominant epitopes and to define mechanisms of autoimmune disease. If the target mouse 
antigen is very different from the human antigen, human transgenes can be introduced, although 
care must be taken to preserve fidelity of expression. 
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